Actinium: social and political problems
What problems does it cause between people, and who carries them?
The main dispute is about old uranium-233 in the United States. One company wrote that the DOE had disposed of a source of thorium-229 that could have made actinium-225 for cancer research1. In 2019 the DOE agreed to extract thorium-229 from the uranium-233 at Oak Ridge first.
Last updated 14 October 2026.
Conflict and disputes
We found no armed conflict or trade dispute linked to actinium.
There was a dispute about uranium-233, the source of thorium-229. In 2018 James Harvey of NorthStar Medical Technologies wrote about one source of thorium-229, old reactor fuel. He wrote that the DOE had sent it to the Nevada Test Site for disposal1. In his view, this meant the permanent loss of about 45 curies of actinium-225 a year1. He also wrote that Congress removed the DOE’s flexibility to use the uranium-233 at Oak Ridge in other ways in 20051. These are the views of NorthStar, a company that develops ways to make actinium-225. We did not find the DOE’s reply to them.
The DOE states that removing uranium-233 from Oak Ridge is the highest priority of its Office of Environmental Management at the laboratory2. In 2019 the DOE, its contractor Isotek and TerraPower agreed to extract thorium-229 before the disposal (see the production chapter).
Workers and communities
We found no recent reports of harm to workers or to communities from actinium.
The known case is historical. Marguerite Perey prepared actinium samples at the Institut du Radium in Paris in the 1930s3. A body scan in 1958 detected actinium throughout her body3. She tried without success to have her disease recognized as an occupational disease3. She died of widespread cancer in 19753. The source does not state that actinium caused the cancer.
Who gains and who loses
In the sources that we read, the main loss is to patients and researchers who cannot get enough actinium-225 (see the power chapter).
The extraction of thorium-229 at Oak Ridge brought money to the disposal project. The DOE states that TerraPower paid Isotek, and that the funds let Isotek move faster, with estimated savings of 90 million dollars to taxpayers2. In 2019 the partners had given the savings as about 90 million dollars per year4. The two sources do not agree on whether the figure is a total or a yearly sum.
Drug companies paid large sums for developers of actinium-225 drugs in 2024 (see the market chapter).
Sources
- 1
James T. Harvey, NorthStar Medical Technologies, in Current Radiopharmaceuticals 11, 2018. NorthStar Perspectives for Actinium-225 Production at Commercial Scale .
A company view of world supply, cost per millicurie, and the disposal of uranium-233 that held thorium-229.
-
DOE has proceeded with the disposal of this source at the Nevada Test Site (NTS)
-
the permanent loss of about 45Ci of annual actinium-225 production
-
Congressional action in 2005 that removed DOE’s flexibility to consider alternative uses, however temporary, of this uranium-233
-
- 2
US Department of Energy, Office of Environmental Management, 2021. Oak Ridge Partnership Expands, Advancing Cancer Treatment Research .
Thorium-229 refining for TerraPower, why thorium-229 only comes from uranium-233, the savings to taxpayers.
-
EM ’s highest priority at the Oak Ridge National Laboratory involves eliminating the inventory of U-233 currently stored in the world’s oldest operating nuclear facility.
-
Isotek, in turn, used the funds it received to accelerate the U-233 disposition project, generating an estimated $90 million in savings to taxpayers.
-
- 3
Anne Fellinger and Soraya Boudia (Charles Scribner's Sons, on Encyclopedia.com), 2008. Perey, Marguerite Catherine, in the Complete Dictionary of Scientific Biography .
Perey's work on actinium sources at the Institut du Radium, and her contamination with actinium.
-
asked her to prepare the most concentrated actiniferous sample ever prepared
-
They realized then that her body was completely contaminated by actinium.
-
She attempted in vain to have her disease recognized as an occupational one
-
dying of widespread cancer in a hospital in Louveciennes, near Paris, on 13 May 1975
-
- 4
World Nuclear News, 2019. Partnership to produce medical isotope from legacy waste .
The 2019 agreement between Isotek, TerraPower and the US DOE on thorium-229 from uranium-233.
-
the US taxpayer will save about USD90 million per year, the partners said
-